Airtame Launches Airtame Cloud, Signaling New Focus on Combined Hardware and Software Offering
Airtame, the leading wireless screen sharing and collaboration platform, today announced the official launch of Airtame Cloud, a new software-as-a-service product designed to make screens smarter. The open platform offers device management and access to a range of digital signage solutions, helping users create smarter offices, workplaces and schools with their screens.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200115005060/en/
Airtame Cloud (Graphic: Business Wire)
Airtame Cloud -- which has been available in beta for over a year, and is already used by 6,500 organizations globally -- is a unified platform that enables users to manage and update their screens remotely. It was built on an open ecosystem that seamlessly integrates with a range of applications that can be used to create tailored digital signage, such as Google Slides, Microsoft OneDrive, Trello, Dropbox, and YouTube, with more integrations to come.
Cloud will allow users to:
- Manage screens remotely, freeing up IT administrators to change settings and conduct bulk updates with cloud access to Airtame-enabled screens
- Boost productivity and engagement, with personalized digital signage in meeting rooms, classrooms and common areas
- Save on power, by scheduling screens to turn on and off according to office or school hours
- Avoid blank screens, by scheduling imagery and videos to play on loop
The launch of Cloud marks the evolution of Airtame as it continues to grow from a hardware to solution-centric business, with a strong focus on facilitating smart offices and schools around the world.
“With Airtame Cloud, we’re providing a solution that empowers our customers to boost engagement and productivity for employees, students and visitors, whether that be in the office, meeting room or classroom,” said Airtame Co-Founder and Co-CEO Jonas Gyalokay.
“Part of our vision at Airtame is to help enterprises and schools create smarter offices and classrooms. While this starts with screens, we imagine one day it could extend to all aspects of the workplace or classroom, with the potential to automate lighting, sound, room temperature and more.
“With the evolution of IoT, the possibilities to connect devices and screens are endless. As a starting point, Airtame Cloud will help schools and enterprises reduce their energy consumption by automating screens to turn off when they’re not being used. We’re looking forward to embracing technology to build additional hardware and software features of this kind in the future.”
Airtame Cloud will launch with two plans: Airtame Cloud Lite, a free version of the product that offers the essential features needed to manage and update Airtame devices, and Airtame Cloud Plus, a premium version that enables digital signage and additional features needed to create a smart office or classroom.
The launch follows a series of important milestones for Airtame, including the recent announcement of its industry-first partnership with Airserver. The company has enjoyed 100% YoY growth since its market launch in 2014.
ENDS
Access the full press kit containing imagery and video materials here.
ABOUT AIRTAME:
Airtame offers a wireless screen sharing and collaboration platform that allows users to instantly display content from any personal device to any shared screen. The platform is used to promote interactivity and collaboration in meetings, presentations and classroom settings, as well as for digital signage in retail stores, corporate environments, conference facilities, hotels, and other venues. Airtame was launched in 2014 and has grown into a company with 100+ people, and with offices in New York, Los Angeles, Copenhagen, and Budapest.
To learn more, visit www.airtame.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200115005060/en/
Contact information
Martin Stockfleth Larsen
Airtame
+45 31 661 663
martin.larsen@airtame.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom